Loyal vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Loyal is a veterinary biotech developing FDA-regulated longevity drugs for dogs; its lead drug LOY-001 received FDA reasonable expectation of effectiveness — the first longevity drug for any species to do so; raised $45M; founded by Celine Halioua.
About
Loyal is a veterinary biotechnology company founded in 2020 by Celine Halioua and headquartered in San Francisco, California. The company is developing pharmaceutical treatments designed to extend the healthspan and lifespan of dogs — large breeds in particular, which age faster and live shorter lives than small breeds. Loyal's approach is grounded in the biology of aging: targeting the hormonal, metabolic, and cellular mechanisms that drive age-related decline in dogs, with the goal of creating FDA-approved drugs that add healthy years to companion animals' lives.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.